NCT03511768

A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 65 (estimated)
• Sponsor: Xiangya Hospital of Central South University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is to investigate the clinical value of \[18F\]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).

Detailed description

18F-AlF-NOTA-octreotide is a radioligand targeting the somatostatin receptor, which is widely expressed on the cell surface of NENs. The radioligand can be used for the diagnosis and stage of the NENs. A total of 5 volunteers and 60 NEN patients will be subjected to a 18F-AlF-NOTA-octreotide PET/CT scan. The uptake of 18F-AlF-NOTA-octreotide in organs and tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean).

Conditions

• Neuroendocrine Neoplasm

Interventions

Type	Name	Description
DRUG	18F-AlF-NOTA-octreotide	One injection of 18F-AlF-NOTA-octreotide
DEVICE	PET/CT	Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT

Timeline

• Start date: 2018-01-02
• Primary completion: 2019-12-30
• Completion: 2020-12-30
• First posted: 2018-04-30
• Last updated: 2018-04-30

Locations

1 site across 1 country: China